Therapeutic regulation of cardiac fibroblast function: Targeting stress-activated protein kinase pathways

Future Cardiology

Volumn 7, Issue 5, 2011, Pages 673-691

  Turner, Neil A ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

cardiac fibroblast; JNK; myocardial remodeling; p38; stress activated protein kinase; therapeutic agents

Indexed keywords

(1,3 BENZOTHIAZOL 2 YL)[2 [2 (3 PYRIDINYL)ETHYLAMINO] 4 PYRIMIDINYL]ACETONITRILE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ALPHA SMOOTH MUSCLE ACTIN; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BIRB 0796; DILMAPIMOD; DORAMAPIMOD; DUAL SPECIFICITY PHOSPHATASE 6; GW 85655; INTERLEUKIN 6; LOSMAPIMOD; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 11; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE 13; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PAMAPIMOD; SCAFFOLD PROTEIN; SD 282; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1; TALMAPIMOD; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 702; XG 102;

ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDITIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR STRESS RESPONSE; CLINICAL FEATURE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; FIBROBLAST; HEART FAILURE; HEART FUNCTION; HEART INJURY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; IN VITRO STUDY; KNOCKOUT MOUSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

FIBROBLASTS; FIBROSIS; HEART; HUMANS; IMIDAZOLES; MAP KINASE KINASE 4; MAP KINASE KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASE 11; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCARDIUM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 80053098655     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.11.41     Document Type: Review

References (121)

1. Weber KT, Brilla CG. Factors associated with reactive and reparative fibrosis of the myocardium. Basic Res. Cardiol. 87(Suppl. 1), 291-301 (1992).
2. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol. Rev. 79, 215-262 (1999). (Pubitemid 29056953)
3. Frantz S, Bauersachs J, Ertl G. Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc. Res. 81, 474-481 (2009).
4. Frangogiannis NG. The immune system and cardiac repair. Pharmacol. Res. 58, 88-111 (2008).
5. Dobaczewski M, Gonzalez-Quesada C, Frangogiannis NG. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J. Mol. Cell. Cardiol. 48, 504-511 (2010).
6. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J. Clin. Invest. 117, 568-575 (2007). (Pubitemid 46348511)
7. Hutchinson KR, Stewart JA Jr, Lucchesi PA. Extracellular matrix remodeling during the progression of volume overload-induced heart failure. J. Mol. Cell. Cardiol. 48, 564-569 (2010).
8. Jugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation 108, 1395-1403 (2003). (Pubitemid 37174420)
9. Banerjee I, Fuseler JW, Price RL, Borg TK, Baudino TA. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am. J. Physiol. Heart Circ. Physiol. 293, H1883-H1891 (2007). (Pubitemid 47367239)
10. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol. Ther. 123, 255-278 (2009).
11. Souders CA, Bowers SL, Baudino TA. Cardiac fibroblast: the renaissance cell. Circ. Res. 105, 1164-1176 (2009).
12. van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat. Rev. Cardiol. 7, 30-37 (2010).
13. Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J. Cell. Physiol. 225, 631-637 (2010).
14. McDowell KS, Trayanova NA, Kohl P. Fibroblasts and cardiac electrophysiology. In: The Cardiac Fibroblast. Turner NA (Ed.).Research Signpost, Kerala, India, 9-27 (2011).
15. Kamkin A, Scholz H, Kiseleva I. Cardiac fibroblasts in normal and diseased heart: Single mechanically-gated ion channels, mechanosensitive currents and mechanically induced potentials in isolated cells and tissue. In: The Cardiac Fibroblast. Turner NA (Ed.).Research Signpost, Kerala, India, 127-142 (2011).
16. Rose BA, Force T, Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol. Rev. 90, 1507-1546 (2010).
17. Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell. Mol. Life Sci. 65, 3525-3544 (2008).
18. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation 116, 1413-1423 (2007). (Pubitemid 47417568)
19. Coulombe P, Meloche S. Atypical mitogen-activated protein kinases: structure, regulation and functions. Biochim. Biophys. Acta 1773, 1376-1387 (2007). (Pubitemid 47125971)
20. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem. J. 429, 403-417 (2010).
21. Clark JE, Sarafraz N, Marber MS. Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease. Pharmacol. Ther. 116, 192-206 (2007). (Pubitemid 47451511)
22. Court NW, dos Remedios CG, Cordell J, Bogoyevitch MA. Cardiac expression and subcellular localization of the p38 mitogen-activated protein kinase member, stress-activated protein kinase-3 (SAPK3).J. Mol. Cell. Cardiol. 34, 413-426 (2002). (Pubitemid 37163457)
23. Jiang Y, Gram H, Zhao M et al. Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38d. J. Biol. Chem. 272, 30122-30128 (1997). (Pubitemid 27512210)
24. Enslen H, Raingeaud J, Davis RJ. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J. Biol. Chem. 273, 1741-1748 (1998). (Pubitemid 28133705)
25. Remy G, Risco AM, Inesta-Vaquera FA et al. Differential activation of p38MAPK isoforms by MKK6 and MKK3. Cell. Signal. 22, 660-667 (2010).
26. Tanno M, Bassi R, Gorog DA et al. Diverse mechanisms of myocardial p38 mitogen-activated protein kinase activation: evidence for MKK-independent activation by a TAB1-associated mechanism contributing to injury during myocardial ischemia. Circ. Res. 93, 254-261 (2003). (Pubitemid 36993237)
27. Whitmarsh AJ. The JIP family of MAPK scaffold proteins. Biochem. Soc. Trans. 34, 828-832 (2006). (Pubitemid 44796431)
28. Bermudez O, Pages G, Gimond C. The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am. J. Physiol. Cell. Physiol. 299, C189-C202 (2010).
29. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 27, 6245-6251 (2008).
30. Bogoyevitch MA, Ngoei KR, Zhao TT, Yeap YY, Ng DC. c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. Biochim. Biophys. Acta 1804, 463-475 (2010).
31. Gupta S, Barrett T, Whitmarsh AJ et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15, 2760-2770 (1996). (Pubitemid 26176253)
32. Golden HB, Verma SK, Lal H et al. Mechanical regulation of stress-activated MAP kinases. In: The Cardiac Fibroblast. Turner NA (Ed.).Research Signpost, Kerala, India, 143-171 (2011).
33. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ et al. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/ reperfusion. Circ. Res. 79, 162-173 (1996). (Pubitemid 26255867)
34. Turner NA, Xia F, Azhar G, Zhang X, Liu L, Wei JY. Oxidative stress induces DNA fragmentation and caspase activation via the c-Jun NH2-terminal kinase pathway in H9c2 cardiac muscle cells. J. Mol. Cell. Cardiol. 30, 1789-1801 (1998). (Pubitemid 28430193)
35. Engelbrecht AM, Niesler C, Page C, Lochner A. p38 and JNK have distinct regulatory functions on the development of apoptosis during simulated ischaemia and reperfusion in neonatal cardiomyocytes. Basic Res. Cardiol. 99, 338-350 (2004). (Pubitemid 39236724)
36. Hernandez OM, Discher DJ, Bishopric NH, Webster KA. Rapid activation of neutral sphingomyelinase by hypoxia-reoxygenation of cardiac myocytes. Circ. Res. 86, 198-204 (2000). (Pubitemid 30086181)
37. Yeh CC, Li H, Malhotra D et al. Distinctive ERK and p38 signaling in remote and infarcted myocardium during post-MI remodeling in the mouse. J. Cell. Biochem. 109, 1185-1191 (2010).
38. Lemke LE, Bloem LJ, Fouts R, Esterman M, Sandusky G, Vlahos CJ. Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK a is the predominant isoform expressed in human heart. J. Mol. Cell. Cardiol. 33, 1527-1540 (2001). (Pubitemid 32681670)
39. Martindale JJ, Wall JA, Martinez-Longoria DM et al. Overexpression of mitogen-activated protein kinase kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo. J. Biol. Chem. 280, 669-676 (2005). (Pubitemid 40165034)
40. Otsu K, Yamashita N, Nishida K et al. Disruption of a single copy of the p38a MAP kinase gene leads to cardioprotection against ischemia-reperfusion. Biochem. Biophys. Res. Comm. 302, 56-60 (2003). (Pubitemid 36268918)
41. Braz JC, Bueno OF, Liang Q et al. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J. Clin. Invest. 111, 1475-1486 (2003). (Pubitemid 38063280)
42. Liao P, Georgakopoulos D, Kovacs A et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc. Natl Acad. Sci. USA 98, 12283-12288 (2001). (Pubitemid 32959865)
43. Engel FB, Schebesta M, Duong MT et al. p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev. 19, 1175-1187 (2005). (Pubitemid 40696184)
44. Rakhit RD, Kabir AN, Mockridge JW, Saurin A, Marber MS. Role of G proteins and modulation of p38 MAPK activation in the protection by nitric oxide against ischemia-reoxygenation injury. Biochem. Biophys. Res. Comm. 286, 995-1002 (2001). (Pubitemid 32924870)
45. Dingar D, Merlen C, Grandy S et al. Effect of pressure overload-induced hypertrophy on the expression and localization of p38 MAP kinase isoforms in the mouse heart. Cell. Signal. 22, 1634-1644 (2010).
46. Adams RH, Porras A, Alonso G et al. Essential role of p38a MAP kinase in placental but not embryonic cardiovascular development. Mol. Cell. 6, 109-116 (2000).
47. Petrich BG, Wang Y. Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies. Trends Cardiovasc. Med. 14, 50-55 (2004). (Pubitemid 38340846)
48. Nishida K, Yamaguchi O, Hirotani S et al. p38a mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload. Mol. Cell. Biol. 24, 10611-10620 (2004). (Pubitemid 39603120)
49. Clerk A, Sugden PH. Inflame my heart (by p38-MAPK).Circ. Res. 99, 455-458 (2006).
50. Marber MS, Rose B, Wang Y. The p38 mitogen-activated protein kinase pathway-A potential target for intervention in infarction, hypertrophy, and heart failure. J. Mol. Cell. Cardiol. doi: 10.1016/j.yjmcc.2010.10.021 (2011) (Epub ahead of print).
51. Bassi R, Heads R, Marber MS, Clark JE. Targeting p38-MAPK in the ischaemic heart: kill or cure? Curr. Opin. Pharmacol. 8, 141-146 (2008).
52. Marber MS, Molkentin JD, Force T. Developing small molecules to inhibit kinases unkind to the heart: p38 MAPK as a case in point. Drug Discov. Today Dis. Mech. 7, e123-e127 (2010).
53. Sicard P, Clark JE, Jacquet S et al. The activation of p38 b, and not p38 b, mitogen-activated protein kinase is required for ischemic preconditioning. J. Mol. Cell. Cardiol. 48, 1324-1328 (2010).
54. Saurin AT, Martin JL, Heads RJ et al. The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes. FASEB J. 14, 2237-2246 (2000).
55. Wang Y, Huang S, Sah VP et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J. Biol. Chem. 273, 2161-2168 (1998). (Pubitemid 28069266)
56. Kim JK, Pedram A, Razandi M, Levin ER. Estrogen prevents cardiomyocyte apoptosis through inhibition of reactive oxygen species and differential regulation of p38 kinase isoforms. J. Biol. Chem. 281, 6760-6767 (2006). (Pubitemid 43847612)
57. Zhang S, Weinheimer C, Courtois M et al. The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J. Clin. Invest. 111, 833-841 (2003). (Pubitemid 37074958)
58. Turner NA, Sinfield JK, Porter KE. TNFa and IL-1 induce IL-6 expression in human cardiac fibroblasts: role of p38 MAP kinase subtypes. J. Mol. Cell. Cardiol. 44, 714 (2008) (Abstract only).
59. Turner NA, Warburton P, O'Regan DJ, Ball SG, Porter KE. Modulatory effect of interleukin-1a on expression of structural matrix proteins, MMPs and TIMPs in human cardiac myofibroblasts: role of p38 MAP kinase. Matrix Biol. 29, 613-620 (2010).
60. Liang Q, Bueno OF, Wilkins BJ, Kuan CY, Xia Y, Molkentin JD. c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling. EMBO J. 22, 5079-5089 (2003). (Pubitemid 37222028)
61. Strait JB, Samarel AM. Isoenzyme-specific protein kinase C and c-Jun N-terminal kinase activation by electrically stimulated contraction of neonatal rat ventricular myocytes. J. Mol. Cell. Cardiol. 32, 1553-1566 (2000).
62. Tachibana H, Perrino C, Takaoka H, Davis RJ, Naga Prasad SV, Rockman HA. JNK1 is required to preserve cardiac function in the early response to pressure overload. Biochem. Biophys. Res. Comm. 343, 1060-1066 (2006).
63. Liu W, Zi M, Jin J et al. Cardiac-specific deletion of mkk4 reveals its role in pathological hypertrophic remodeling but not in physiological cardiac growth. Circ. Res. 104, 905-914 (2009).
64. Liu W, Zi M, Chi H et al. Deprivation of MKK7 in cardiomyocytes provokes heart failure in mice when exposed to pressure overload. J. Mol. Cell. Cardiol. 50(4), 702-711 (2011).
65. Wei J, Wang W, Chopra I et al. C-Jun N-terminal kinase (JNK-1) confers protection against brief but not extended ischemia during acute myocardial infarction. J. Biol. Chem. 286(16), 13995-14006 (2011).
66. Bain J, Plater L, Elliott M et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297-315 (2007).
67. Kuma Y, Sabio G, Bain J, Shpiro N, Márquez R, Cuenda A. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J. Biol. Chem. 280, 19472-19479 (2005). (Pubitemid 41379467)
68. Sweeney SE. The as-yet unfulfilled promise of p38 MAPK inhibitors. Nat. Rev. Rheumatol. 5, 475-477 (2009).
69. Sarov-Blat L, Morgan JM, Fernandez P et al. Inhibition of p38 mitogen-activated protein kinase reduces inflammation after coronary vascular injury in humans. Arterioscler. Thromb. Vasc. Biol. 30, 2256-2263 (2010).
70. Siddiqui MA, Reddy PA. Small molecule JNK (c-Jun N-terminal kinase) inhibitors. J. Med. Chem. 53, 3005-3012 (2010).
71. Kyoi S, Otani H, Matsuhisa S et al. Opposing effect of p38 MAP kinase and JNK inhibitors on the development of heart failure in the cardiomyopathic hamster. Cardiovasc. Res. 69, 888-898 (2006). (Pubitemid 43227987)
72. Wu W, Muchir A, Shan J, Bonne G, Worman HJ. Mitogen-activated protein kinase inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by mutation in lamin A/C gene. Circulation 123, 53-61 (2011).
73. Ferrandi C, Ballerio R, Gaillard P et al. Inhibition of c-Jun N-terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats. Br. J. Pharmacol. 142, 953-960 (2004). (Pubitemid 39037045)
74. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF. Cell-permeable peptide inhibitors of JNK: novel blockers of b-cell death. Diabetes 50, 77-82 (2001). (Pubitemid 32047984)
75. Milano G, Morel S, Bonny C et al. A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo. Am. J. Physiol. Heart Circ. Physiol. 292, H1828-H1835 (2007). (Pubitemid 46572407)
76. Liu J, Sadoshima J, Zhai P et al. Pressure overload induces greater hypertrophy and mortality in female mice with p38a MAPK inhibition. J. Mol. Cell. Cardiol. 41, 680-688 (2006). (Pubitemid 44374540)
77. Turner NA, Das A, Warburton P, O'Regan DJ, Ball SG, Porter KE. Interleukin-1a stimulates pro-inflammatory cytokine expression in human cardiac myofibroblasts. Am. J. Physiol. Heart Circ. Physiol. 297, H1117-H1127 (2009).
78. Turner NA, Mughal RS, Warburton P, O'Regan DJ, Ball SG, Porter KE. Mechanism of TNFa-induced IL-1a, IL-1b and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovasc. Res. 76, 81-90 (2007). (Pubitemid 47362045)
79. Sano M, Fukuda K, Sato T et al. ERK and p38 MAPK, but not NF-kB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts. Circ. Res. 89, 661-669 (2001). (Pubitemid 34627065)
80. Feng W, Song Y, Chen C, Lu ZZ, Zhang Y. Stimulation of adenosine A2B receptors induces interleukin-6 secretion in cardiac fibroblasts via the PKC-d-P38 signalling pathway. Br. J. Pharmacol. 159, 1598-1607 (2010).
81. Yin F, Wang YY, Du JH et al. Noncanonical cAMP pathway and p38 MAPK mediate b2-adrenergic receptor-induced IL-6 production in neonatal mouse cardiac fibroblasts. J. Mol. Cell. Cardiol. 40, 384-393 (2006). (Pubitemid 43277840)
82. Du JH, Xu N, Song Y et al. AICAR stimulates IL-6 production via p38 MAPK in cardiac fibroblasts in adult mice: a possible role for AMPK. Biochem. Biophys. Res. Comm. 337, 1139-1144 (2005). (Pubitemid 41509193)
83. Omura T, Yoshiyama M, Kim S et al. Involvement of apoptosis signal-regulating kinase-1 on angiotensin II-induced monocyte chemoattractant protein-1 expression. Arterioscler. Thromb. Vasc. Biol. 24, 270-275 (2004). (Pubitemid 38197577)
84. Hohensinner PJ, Kaun C, Rychli K et al. The inflammatory mediator oncostatin M induces stromal derived factor-1 in human adult cardiac cells. FASEB J. 23, 774-782 (2009).
85. Scheuren N, Jacobs M, Ertl G, Schorb W. Cyclooxygenase-2 in myocardium stimulation by angiotensin-II in cultured cardiac fibroblasts and role at acute myocardial infarction. J. Mol. Cell. Cardiol. 34, 29-37 (2002). (Pubitemid 34146393)
86. Kacimi R, Karliner JS, Koudssi F, Long CS. Expression and regulation of adhesion molecules in cardiac cells by cytokines: response to acute hypoxia. Circ. Res. 82, 576-586 (1998). (Pubitemid 28129028)
87. Tenhunen O, Rysa J, Ilves M, Soini Y, Ruskoaho H, Leskinen H. Identification of cell cycle regulatory and inflammatory genes as predominant targets of p38 mitogen-activated protein kinase in the heart. Circ. Res. 99, 485-493 (2006). (Pubitemid 44337820)
88. Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 56, 225-231 (2010).
89. Cortez DM, Feldman MD, Mummidi S et al. IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP-b, NF-kB, and AP-1 activation. Am. J. Physiol. Heart Circ. Physiol. 293, H3356-H3365 (2007). (Pubitemid 350230876)
90. Brown RD, Jones GM, Laird RE, Hudson P, Long CS. Cytokines regulate matrix metalloproteinases and migration in cardiac fibroblasts. Biochem. Biophys. Res. Comm. 362, 200-205 (2007). (Pubitemid 47304407)
91. Luque A, Carpizo DR, Iruela-Arispe ML. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J. Biol. Chem. 278, 23656-23665 (2003). (Pubitemid 36830188)
92. See F, Thomas W, Way K et al. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J. Am. Coll. Cardiol. 44, 1679-1689 (2004). (Pubitemid 39369804)
93. Tang M, Zhong M, Shang Y et al. Differential regulation of collagen types I and III expression in cardiac fibroblasts by AGEs through TRB3/MAPK signaling pathway. Cell. Mol. Life Sci. 65, 2924-2932 (2008).
94. Yu XY, Qiao SB, Guan HS, Liu SW, Meng XM. Effects of visfatin on proliferation and collagen synthesis in rat cardiac fibroblasts. Horm. Metab. Res. 42, 507-513 (2010).
95. Weiss TW, Kvakan H, Kaun C et al. The gp130 ligand oncostatin M regulates tissue inhibitor of metalloproteinases-1 through ERK1/2 and p38 in human adult cardiac myocytes and in human adult cardiac fibroblasts: a possible role for the gp130/gp130 ligand system in the modulation of extracellular matrix degradation in the human heart. J. Mol. Cell. Cardiol. 39, 545-551 (2005). (Pubitemid 41133740)
96. Lal H, Verma SK, Golden HB, Foster DM, Smith M, Dostal DE. Stretch-induced regulation of angiotensinogen gene expression in cardiac myocytes and fibroblasts: opposing roles of JNK1/2 and p38a MAP kinases. J. Mol. Cell. Cardiol. 45, 770-778 (2008).
97. Verma SK, Lal H, Golden HB et al. Rac1 and RhoA differentially regulate angiotensinogen gene expression in stretched cardiac fibroblasts. Cardiovasc. Res. 90, 88-96 (2011).
98. Yin H, Zhang J, Lin H et al. p38 mitogen-activated protein kinase inhibition decreases TNFa secretion and protects against left ventricular remodeling in rats with myocardial ischemia. Inflammation 31, 65-73 (2008). (Pubitemid 351388889)
99. Thandavarayan RA, Watanabe K, Ma M et al. Dominant-negative p38a mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus. Am. J. Physiol. Heart Circ. Physiol. 297, H911-H919 (2009).
100. Kompa AR, See F, Lewis DA et al. Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction. J. Pharmacol. Exp. Ther. 325, 741-750 (2008). (Pubitemid 351724310)
101. Mitchell MD, Laird RE, Brown RD, Long CS. IL-1b stimulates rat cardiac fibroblast migration via MAP kinase pathways. Am. J. Physiol. Heart Circ. Physiol. 292, H1139-H1147 (2007).
102. Cooper M, Ytrehus K. Cell survival signalling in heart derived myofibroblasts induced by preconditioning and bradykinin: the role of p38 MAP kinase. Mol. Cell. Biochem. 259, 83-90 (2004). (Pubitemid 38519219)
103. Nishida M, Onohara N, Sato Y et al. Ga12/13-mediated up-regulation of TRPC6 negatively regulates endothelin-1-induced cardiac myofibroblast formation and collagen synthesis through nuclear factor of activated T cells activation. J. Biol. Chem. 282, 23117-23128 (2007). (Pubitemid 47311958)
104. Fix C, Bingham K, Carver W. Effects of interleukin-18 on cardiac fibroblast function and gene expression. Cytokine 53, 19-28 (2011).
105. Dahl CP, Husberg C, Gullestad L et al. Increased production of CXCL16 in experimental and clinical heart failure: a possible role in extracellular matrix remodeling. Circ. Heart Fail. 2, 624-632 (2009).
106. Xie Z, Singh M, Singh K. Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1b. J. Biol. Chem. 279, 39513-39519 (2004). (Pubitemid 39258218)
107. Schellings MW, Pinto YM, Heymans S. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc. Res. 64, 24-31 (2004). (Pubitemid 39208920)
108. Zou P, Wu LL, Wu D et al. High glucose increases periostin expression and the related signal pathway in adult rat cardiac fibroblasts. Sheng Li Xue Bao 62, 247-254 (2010).
109. Xie Z, Singh M, Singh K. ERK1/2 and JNKs, but not p38 kinase, are involved in reactive oxygen species-mediated induction of osteopontin gene expression by angiotensin II and interleukin-1b in adult rat cardiac fibroblasts. J. Cell. Physiol. 198, 399-407 (2004). (Pubitemid 38235035)
110. Omura T, Yoshiyama M, Matsumoto R et al. Role of c-Jun NH2-terminal kinase in G-protein-coupled receptor agonist-induced cardiac plasminogen activator inhibitor-1 expression. J. Mol. Cell. Cardiol. 38, 583-592 (2005). (Pubitemid 40461822)
111. Turner NA. Therapeutic strategies for targeting the cardiac fibroblast. In: The Cardiac Fibroblast. Turner NA (Ed.).Research Signpost, Kerala, India, 273-285 (2011).
112. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Ann. Rev. Pharmacol. Toxicol. 45, 657-687 (2005). (Pubitemid 40261821)
113. Brown RD, Mitchell MD, Long CS. Proinflammatory cytokines and cardiac extracellular matrix: regulation of fibroblast phenotype. In: Interstitial Fibrosis in Heart Disease. Villareal FJ (Ed.).Springer, NY, USA, 57-81 (2004).
114. Korb A, Tohidast-Akrad M, Cetin E, Axmann R, Smolen J, Schett G. Differential tissue expression and activation of p38 MAPK a, b, g, and d isoforms in rheumatoid arthritis. Arthritis Rheum. 54, 2745-2756 (2006). (Pubitemid 44497753)
115. Zheng B, Zhang Z, Black CM, de Crombrugghe B, Denton CP. Ligand-dependent genetic recombination in fibroblasts: a potentially powerful technique for investigating gene function in fibrosis. Am. J. Pathol. 160, 1609-1617 (2002). (Pubitemid 34525641)
116. Takeda N, Manabe I, Uchino Y et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J. Clin. Invest. 120, 254-265 (2010).
117. Conway SJ, Molkentin JD. Periostin as a heterofunctional regulator of cardiac development and disease. Curr. Genomics 9, 548-555 (2008).
118. Zaglia T, Dedja A, Candiotto C, Cozzi E, Schiaffino S, Ausoni S. Cardiac interstitial cells express GATA4 and control dedifferentiation and cell cycle re-entry of adult cardiomyocytes. J. Mol. Cell. Cardiol. 46, 653-662 (2009).
119. Bian J, Popovic ZB, Benejam C, Kiedrowski M, Rodriguez LL, Penn MS: Effect of cell-based intercellular delivery of transcription factor GATA4 on ischemic cardiomyopathy. Circ. Res. 100, 1626-1633 (2007). (Pubitemid 46900752)
120. Ruvinov E, Sharabani-Yosef O, Nagler A et al. Transplantation of genetically engineered cardiac fibroblasts producing recombinant human erythropoietin to repair the infarcted myocardium. Fibrogen. Tiss. Rep. 1(1), 7 (2008).
121. Goncalves GA, Vassallo PF, Dos SL et al. Intramyocardial transplantation of fibroblasts expressing vascular endothelial growth factor attenuates cardiac dysfunction. Gene Ther. 17, 305-314 (2010).